Your Trusted Brand for Over 35 Years

Daily News

Recent Findings in Prostate Cancer Described by A.T. Toriola and Colleagues


By a News Reporter-Staff News Editor at Blood Weekly -- Current study results on Oncology have been published. According to news reporting from Kotka, Finland, by NewsRx journalists, research stated, "Accruing evidence suggests that inflammation plays a role in prostate carcinogenesis. However, studies evaluating this association using C-reactive protein (CRP) and interleukin-6 as markers of inflammation have reported conflicting results."

The news correspondents obtained a quote from the research, "We investigated the associations of three common markers of inflammation (CRP, fibrinogen and leukocyte count) with the risk of prostate cancer in a prospective cohort of 2,571 men from Finland. During an average follow-up period of 24 years (21-26 years), 203 men from the cohort who developed prostate cancer were identified via linkage to the nationwide Finnish Cancer Registry. We investigated the associations between the markers and the risk of prostate cancer using Cox proportional hazards model, adjusting for potential confounders. Elevated prediagnostic leukocyte count was associated with an increased risk of prostate cancer. In multivariable adjusted model, the relative risk of prostate cancer among men in the highest tertile of leukocyte count compared to men in the lowest tertile was 1.60 (95% confidence interval [CI] = 1.10-2.29, p-trend = 0.01). Circulating CRP and fibrinogen were not associated with increased risk. The corresponding relative risks for elevated CRP and fibrinogen concentrations were 1.08 (95% CI: 0.74-1.60, p-trend = 0.56) and 1.25 (95% CI: 0.87-1.81, p-trend = 0.14), respectively. Men with elevated leukocyte counts had a 2.57-fold (95% CI: 0.99-6.79) increased risk of prostate cancer mortality. The increased risk associated with elevated leukocyte counts warrants confirmation in other studies."

According to the news reporters, the research concluded: "Larger studies should consider combining at least two markers or using an inflammation score derived from many inflammatory markers to evaluate prostate cancer risk."

For more information on this research see: Prediagnostic circulating markers of inflammation and risk of prostate cancer. International Journal of Cancer, 2013;133(12):2961-2967. International Journal of Cancer can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell -; International Journal of Cancer -

Our news journalists report that additional information may be obtained by contacting A.T. Toriola, Municipal Author Med & Social Serv Kymenlaakso, Kymenlaakso Hosp Serv, Clin Chem Lab, Kotka, Finland. Additional authors for this research include J.A. Laukkanen, S. Kurl, K. Nyyssonen, K. Ronkainen and J. Kauhanen (see also Oncology).

Keywords for this news article include: Kotka, Europe, Finland, Oncology, Fibrinogen, Immunology, Leukocytes, Blood Cells, Inflammation, Immune System, Protein Precursors, Prostatic Neoplasms, Risk and Prevention, Acute-Phase Proteins, Blood Coagulation Factors, Metastatic Prostate Cancer

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC

To see more of the, or to subscribe, go to .

Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.